![]() |
|
|
1 Laboratory of Chemical Pharmacology, National Heart Institute, and Laboratory of Experimental Pathology, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Maryland
In the paper entitled "Neurologic, Neuropathologic, and Neurochemical Effects of Prolonged Administration of Phenylisopropylhydrazine (JB 516), Phenylisobutylhydrazine (JB 835), and Other Monoamine Oxidase Inhibitors" by H. M. Maling, B. Highman and S. Spector (Vol. 137, No. 3, September 1962), there is an error on page 338, table 4, last column, line 5. The 3.2 mg/kg oral daily dose of JB 516 showed an incidence of lesions in the pyriform lobe of 0/4 instead of 2/4 as printed.